OncoMatch/Clinical Trials/NCT06126510
Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Is NCT06126510 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 for sarcoma.
Treatment: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 — This study plans to use 1.0×108PFU/day per cycle, intratumoral injection administration for 3 consecutive days, and 28 days as a cycle. Tumor imaging evaluation was performed every 8±1 weeks from the first dose of C1D1 until an event that met the criteria for treatment discontinuation occurred.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Biomarker criteria
Required: HSV1 positive IgG or IgM antibody test
Those who have a positive HSV-1 IgG or HSV-1 IgM antibody test result (HSV-1 IgM).
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard treatment
have failed at least one standard treatment (among them, patients with Ewing sarcoma need to be patients without standard treatment)
Cannot have received: chemotherapy
Exception: within 4 weeks before the first use of study drugs
Have received chemotherapy...within 4 weeks before the first use of study drugs
Cannot have received: radiotherapy
Exception: within 4 weeks before the first use of study drugs
Have received...radiotherapy...within 4 weeks before the first use of study drugs
Cannot have received: biological therapy
Exception: within 4 weeks before the first use of study drugs
Have received...biological therapy...within 4 weeks before the first use of study drugs
Cannot have received: endocrine therapy
Exception: within 4 weeks before the first use of study drugs
Have received...endocrine therapy...within 4 weeks before the first use of study drugs
Cannot have received: targeted therapy
Exception: within 4 weeks before the first use of study drugs; oral fluorouracils and small molecule targeted drugs: within 2 weeks or 5 half-lives (whichever is longer)
Have received...targeted therapy...within 4 weeks before the first use of study drugs, among which oral fluorouracils and small molecule targeted drugs...within the first 2 weeks or the 5 half-lives of the drug (whichever is longer)
Cannot have received: immunotherapy
Exception: within 4 weeks before the first use of study drugs
Have received...immunotherapy...within 4 weeks before the first use of study drugs
Cannot have received: other anti-tumor drugs
Exception: within 4 weeks before the first use of study drugs
Have received...other anti-tumor drugs within 4 weeks before the first use of study drugs
Cannot have received: unmarketed clinical trial treatments
Exception: within 4 weeks before using the study drug for the first time
Have received other unmarketed clinical trial treatments within 4 weeks before using the study drug for the first time
Lab requirements
Blood counts
ANC≥1.5×10^9/L, PLT≥75×10^9/L, Hb≥85g/L, lymphocyte count≥1.5×10^9/L (0.8–1.5×10^9/L at investigator discretion)
Kidney function
Cr≤1.5×ULN, and creatinine clearance ≥45ml/min (Cockcroft-Gault formula)
Liver function
TBIL ≤1.5×ULN, ALT≤3×ULN, AST≤3×ULN (ALT≤5×ULN and AST≤5×ULN are acceptable for patients with liver metastases)
Cardiac function
QTc interval>480ms, NYHA class ≥II or LVEF<40%, uncontrolled hypertension (SBP≥140mmHg or DBP≥90mmHg after treatment), ventricular arrhythmias requiring intervention, acute coronary syndrome, CHF, stroke or other grade III+ cardiovascular events within 6 months
Have adequate organ function: Blood routine...Liver function...Renal function...Coagulation function...History of severe cardiovascular disease...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06126510 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy, biological therapy disqualifies patients from enrollment.
Does this trial require HSV1?
Yes, HSV1 positive IgG or IgM antibody test is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages